Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR 1,717.10
+16.60 (0.98%)
At close: Feb 17, 2026
NSE:SUNPHARMA Revenue
Sun Pharmaceutical Industries had revenue of 155.21B INR in the quarter ending December 31, 2025, with 13.49% growth. This brings the company's revenue in the last twelve months to 568.09B, up 10.09% year-over-year. In the fiscal year ending March 31, 2025, Sun Pharmaceutical Industries had annual revenue of 525.78B with 8.42% growth.
Revenue (ttm)
568.09B
Revenue Growth
+10.09%
P/S Ratio
7.25
Revenue / Employee
13.21M
Employees
43,000
Market Cap
4.12T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 525.78B | 40.82B | 8.42% |
| Mar 31, 2024 | 484.97B | 46.11B | 10.51% |
| Mar 31, 2023 | 438.86B | 52.31B | 13.53% |
| Mar 31, 2022 | 386.54B | 51.56B | 15.39% |
| Mar 31, 2021 | 334.98B | 6.61B | 2.01% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 331.82B |
| Cipla | 279.67B |
| Zydus Lifesciences | 260.89B |
| Glenmark Pharmaceuticals | 165.10B |
| Alkem Laboratories | 142.53B |
| Mankind Pharma | 139.14B |
| Divi's Laboratories | 103.14B |
| Ipca Laboratories | 95.06B |
Sun Pharmaceutical Industries News
- 3 days ago - Speeding SUV kills food delivery agent on Sun Pharma Road - The Times of India
- 14 days ago - India-US trade deal clarity: Pharma exporters gain edge in US; sector eyes growth boost - The Times of India
- 14 days ago - Sun Pharma receives FDA Rare Pediatric Disease Priority Review Voucher for Sezaby - Business Upturn
- 14 days ago - Sun Pharmaceuticals Industries Ltd (BOM:524715) Q3 2026 Earnings Call Highlights: Strong Sales ... - GuruFocus
- 15 days ago - Q3 2026 Sun Pharmaceutical Industries Ltd Earnings Call Transcript - GuruFocus
- 16 days ago - Pharma sector stocks today, Feb 1: Shilpa Medicare rally 8%, Sun Pharma up 3%, Aurobindo Pharma falls 2.21% - Business Upturn
- 16 days ago - Sun Pharma shares jump over 3% as revenue rises 13.5% YoY to Rs 15,469.1 crore, net profit up 16% - Business Upturn
- 17 days ago - Sun Pharma board declares interim dividend of Rs 11 per share for FY26 - Business Upturn